Oral cohort

DRUG2 trials

Sponsors

G2GBio, Inc.

Conditions

Alzheimer Disease

Phase 1

Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers

CompletedNCT05525780

G2GBio, Inc.Alzheimer Disease

Start: 2022-08-26End: 2023-06-02Updated: 2023-07-13

Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers

G2GBio, Inc.Alzheimer Disease

Start: 2024-01-03End: 2025-01-14Target: 56Updated: 2023-12-22

Related Papers

Population Pharmacokinetic Modeling and Simulation for Dose Optimization of GB-5001, a Long-Acting Intramuscular Injection of Donepezil, in Healthy Participants.

2024-08-101 citations